Tachihara Motoko 立原素子

Researcher Number	40448626
Other IDs
Affiliation (Current)	2025: 神戸大学, 医学部附属病院, 准教授
Affiliation (based on the past Project Information) *help	2021 – 2023: 神戸大学, 医学研究科, 特命准教授 2019 – 2020: 神戸大学, 医学研究科, 講師 2017 – 2018: 神戸大学, 医学研究科, 助教 2013 – 2015: 神戸大学, 医学(系)研究科(研究院), 助教
Review Section/Research Field	Principal Investigator Basic Section 53030:Respiratory medicine-related / Respiratory organ internal medicine Except Principal Investigator Respiratory organ internal medicine
Keywords	Principal Investigator 肺がん / lung cancer / ICI / anamorelin / 抗PD-1抗体 / アナモレリン / 小細胞肺がん / 形質転換 / 非小細胞肺がん / がん幹細胞 … More / 老化細胞 / 幹細胞 / ALK-TKI / 国際情報交換 / アンフィレグリン / 薬剤耐性 / アムルビシン … More Except Principal Investigator 癌 / 三次元培養 / 肺がん / オルガノイド培養 / スパイラルアレイ / 微小乳頭状構造 / 免疫染色 / 肺腺癌 / CARD9 / 非小細胞肺がん Less

The interaction between anamorelin and immune checkpoint inhibitors and its mechanism of actionPrincipal Investigator
- Principal Investigator
  
  立原素子
- Project Period (FY)
  2023 – 2025
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53030:Respiratory medicine-related
- Research Institution
  Kobe University
Overcoming resistance to molecular targeted drugs targeting cancer stem cells and senescent cellsPrincipal Investigator
- Principal Investigator
  
  Tachihara Motoko
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53030:Respiratory medicine-related
- Research Institution
  Kobe University
Novel prognostic factor for lung adenocarcinoma
- Principal Investigator
  
  Nagano Tatsuya
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kobe University
Analysis of resistance mechanism to amrubicinPrincipal Investigator
- Principal Investigator
  
  Tachihara Motoko
- Project Period (FY)
  2013 – 2015
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kobe University

All 2023 2022 2016 2015

All Journal Article Presentation

[Journal Article] Association of<i>STAT3, CYP3A5</i>, and<i>ABCG2</i>Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients2023
- Author(s)
  TANDA MASAAKI、YAMAMOTO KAZUHIRO、HORI TOMOKI、NISHIGUCHI HIROKI、YAGI MIKI、SHIMIZU MICHIKO、KONISHI TORU、OZAKI TOMONORI、YOSHIOKA NATSUE、TACHIHARA MOTOKO、ITO TAKEFUMI、IKUSHIMA SHIGEKI、OMURA TOMOHIRO、YANO IKUKO
- Journal Title
  
  Anticancer Research
  
  Volume: 43 Issue: 4 Pages: 1775-1783
- DOI
  10.21873/anticanres.16331
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K06697, KAKENHI-PROJECT-20K08518
[Journal Article] Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates2022
- Author(s)
  Suraya Ratoe、Tachihara Motoko、Nagano Tatsuya、Nishimura Yoshihiro、Kobayashi Kazuyuki
- Journal Title
  
  Cancer Management and Research
  
  Volume: Volume 14 Pages: 2079-2090
- DOI
  10.2147/cmar.s366738
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08518, KAKENHI-PROJECT-20K08567
[Journal Article] Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer2022
- Author(s)
  Nagano Tatsuya、Tachihara Motoko、Tanaka Yugo
- Journal Title
  
  Journal of Thoracic Disease
  
  Volume: 14 Issue: 4 Pages: 809-811
- DOI
  10.21037/jtd-22-57
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08518, KAKENHI-PROJECT-20K08567
[Journal Article] ROS1-Rearranged Lung Cancer Successfully Resected after Response to Crizotinib: A Case Report2022
- Author(s)
  Shimizu N, Tanaka Y, Tachihara M, Maniwa Y
- Journal Title
  
  Kobe J Med Sci
  
  Volume: 67(4)
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08518
[Journal Article] Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer2022
- Author(s)
  Fukui Takafumi、Tachihara Motoko、Nagano Tatsuya、Kobayashi Kazuyuki
- Journal Title
  
  Cancers
  
  Volume: 14 Issue: 5 Pages: 1184-1184
- DOI
  10.3390/cancers14051184
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08518, KAKENHI-PROJECT-20K08567
[Journal Article] TAPO in first‐line osimertinib therapy and continuation of osimertinib2022
- Author(s)
  Mimura Chihiro、Kaneshiro Kazumi、Fujimoto Shodai、Dokuni Ryota、Iwamoto Natsuhiko、Matsumura Kanoko、Hatakeyama Yukihisa、Kono Yuko、Tachihara Motoko
- Journal Title
  
  Thoracic Cancer
  
  Volume: 14 Issue: 6 Pages: 584-591
- DOI
  10.1111/1759-7714.14782
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08518
[Presentation] ALK-TKI治療中にBRAF V600E変異が検出された若年発症HIP1-ALK陽性肺癌の一例2023
- Author(s)
  大木元愛子、桂田直子、立原　素子、山本　正嗣、矢谷　敦彦、羽間　大祐、小林　和幸
- Organizer
  第117回日本肺癌学会関西支部学術集会
- Data Source
  KAKENHI-PROJECT-20K08518
[Presentation] 第 1・2 世代 EGFR-TKI およびプラチナ PD（T790M 陰性）を示した EGFR 陽性 NSCLC に対するオシメルチニブの第 2 相試験2022
- Author(s)
  武田真幸, 下川元継, 中村敦, 野崎要, 渡辺恭孝, 加藤晃史, 早川乃介, 田中洋史, 高橋利明, 立原素子, 林秀敏, 藤本大智, 山口覚博, 山本将一朗, 岩間映二, 東公一, 沖昌英, 長谷川一男, 山本信之, 中川和彦
- Organizer
  第63回日本肺癌学会学術集会
- Data Source
  KAKENHI-PROJECT-20K08518
[Presentation] 免疫組織化学法とマルチプレックス検査によるALK融合遺伝子発現の検討2022
- Author(s)
  三村千尋、立原素子、福井崇文、山田潤、矢谷敦彦、福田貴与子、羽間大祐、桂田直子、永野達也、山本正嗣、小林和幸
- Organizer
  第63回日本肺癌学会学術集会
- Data Source
  KAKENHI-PROJECT-20K08518
[Presentation] A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration2022
- Author(s)
  Chihiro Mimura, Motoko Tachihara, Kazumi Kaneshiro, Yuko Kono, Shodai Fujimoto, Yukihisa Hatakeyama, Ryota Dokuni, Natsuhiko Iwamoto, Kanoko Matsumura, Kazuyuki Kobayashi
- Organizer
  ESMO2022
- Data Source
  KAKENHI-PROJECT-20K08518
[Presentation] 肺癌細胞株におけるアムルビシン耐性化機序の検討2016
- Author(s)
  徳永俊太郎、永野達也、國政啓、田村大介、山本正嗣、立原素子、小林和幸、西村善博
- Organizer
  第56回日本呼吸器学会学術講演会
- Place of Presentation
  京都
- Year and Date
  2016-04-09
- Data Source
  KAKENHI-PROJECT-25461158
[Presentation] Amrubicinol耐性肺がん細胞株でのamphiregulinの発現の上昇2015
- Author(s)
  徳永俊太郎、永野達也、國政啓、田村大介、立原素子、小林和幸、西村善博
- Organizer
  第74回日本癌学会総会
- Place of Presentation
  名古屋
- Year and Date
  2015-10-09
- Data Source
  KAKENHI-PROJECT-25461158

1. NAGANO TATSUYA (80624684)

# of Collaborated Projects: 4 results

# of Collaborated Products: 6 results
2. NISHIMURA YOSHIHIRO (20291453)

# of Collaborated Projects: 3 results

# of Collaborated Products: 3 results
3. KOBAYASHI KAZUYUKI (50403275)

# of Collaborated Projects: 2 results

# of Collaborated Products: 7 results
4. TAMURA DAISUKE (80646597)

# of Collaborated Projects: 2 results

# of Collaborated Products: 2 results
5. 山本正嗣 (40542139)

# of Collaborated Projects: 2 results

# of Collaborated Products: 3 results
6. 小谷義一 (90403287)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 羽間大祐 (30894604)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 矢野育子

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
9. 山本和宏

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Tachihara Motoko 立原 素子

Research Projects

Research Products

Co-Researchers

The interaction between anamorelin and immune checkpoint inhibitors and its mechanism of actionPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Overcoming resistance to molecular targeted drugs targeting cancer stem cells and senescent cellsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Novel prognostic factor for lung adenocarcinoma

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Analysis of resistance mechanism to amrubicinPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Association of<i>STAT3, CYP3A5</i>, and<i>ABCG2</i>Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] ROS1-Rearranged Lung Cancer Successfully Resected after Response to Crizotinib: A Case Report2022

Author(s)

Journal Title

Data Source

[Journal Article] Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] TAPO in first‐line osimertinib therapy and continuation of osimertinib2022

Author(s)

Journal Title

DOI

Data Source

[Presentation] ALK-TKI治療中にBRAF V600E変異が検出された若年発症HIP1-ALK陽性肺癌の一例2023

Author(s)

Organizer

Data Source

[Presentation] 第 1・2 世代 EGFR-TKI およびプラチナ PD（T790M 陰性）を示した EGFR 陽性 NSCLC に 対するオシメルチニブの第 2 相試験2022

Author(s)

Organizer

Data Source

[Presentation] 免疫組織化学法とマルチプレックス検査によるALK融合遺伝子発現の検討2022

Author(s)

Organizer

Data Source

[Presentation] A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration2022

Author(s)

Organizer

Data Source

[Presentation] 肺癌細胞株におけるアムルビシン耐性化機序の検討2016

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] Amrubicinol耐性肺がん細胞株でのamphiregulinの発現の上昇2015

Tachihara Motoko 立原素子

[Presentation] 第 1・2 世代 EGFR-TKI およびプラチナ PD（T790M 陰性）を示した EGFR 陽性 NSCLC に対するオシメルチニブの第 2 相試験2022